院前急救血液采集可缩短急性胸痛患者急诊停留时间
本研究为前瞻性观察性队列研究,纳入2016年12月至2018年4月三家院前急救机构的401例非创伤性胸痛且无ST段抬高型心肌梗死成人患者。急救人员在转运途中采集血样直接送医院核心实验室测肌钙蛋白,急诊医师对院前肌钙蛋白结果设盲,按标准诊疗完成HEART Pathway评估。结果显示,利用院前血样测肌钙蛋白可使急诊停留时间平均潜在缩短72.5±35.7分钟;30天主要不良心脏事件发生率为21.0%(84/401)。HEART Pathway联合院前及急诊到院肌钙蛋白的阴性预测值为98.0%(95%CI:89.6-100),联合院前及急诊3小时肌钙蛋白的阴性预测值提高至100%(95%CI:92.9-100)。作者认为,院前采血用于核心实验室肌钙蛋白检测可显著缩短急诊停留时间,整合入HEART Pathway时似乎安全。
要点
- 401例急性胸痛患者中,利用院前急救血样测肌钙蛋白可使急诊停留时间平均潜在缩短72.5±35.7分钟。
- 30天主要不良心脏事件发生率为21.0%(84/401),包括1例心源性死亡、78例心肌梗死和5例无心肌梗死的血运重建。
- HEART Pathway联合院前及急诊到院肌钙蛋白的阴性预测值为98.0%(95%CI:89.6-100)。
- HEART Pathway联合院前及急诊3小时肌钙蛋白的阴性预测值提高至100%(95%CI:92.9-100)。
- 急诊医师对院前肌钙蛋白结果设盲,院前采血整合入HEART Pathway时似乎安全。
适用人群与场景
- 美国三家院前急救机构于2016年12月至2018年4月转运的成人非创伤性胸痛患者,且无ST段抬高型心肌梗死。
处置流程与药物剂量
- 急救人员在转运途中采集患者血样,直接送至医院核心实验室测肌钙蛋白。
- 急诊到院后由急诊医师按标准诊疗完成HEART Pathway评估,急诊医师对院前血样肌钙蛋白结果设盲。
研究设计与关键结果
- 研究为前瞻性观察性队列研究,纳入401例急性胸痛患者,院前急救采血测肌钙蛋白使急诊停留时间平均潜在缩短72.5±35.7分钟。
- 30天主要不良心脏事件发生率为21.0%(84/401),其中心源性死亡1例、心肌梗死78例、无心肌梗死的血运重建5例。
- HEART Pathway联合院前及急诊到院肌钙蛋白的阴性预测值为98.0%(95%CI:89.6-100)。
- HEART Pathway联合院前及急诊3小时肌钙蛋白的阴性预测值为100%(95%CI:92.9-100)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,院前急救采血用于核心实验室急诊肌钙蛋白检测可显著缩短急诊停留时间,整合入HEART Pathway时似乎安全。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Expediting the measurement of serum troponin by leveraging EMS blood collection could reduce the diagnostic time for patients with acute chest pain and help address Emergency Department (ED) overcrowding. However, this practice has not been examined among an ED chest pain patient population in the United States.
METHODS: A prospective observational cohort study of adults with non-traumatic chest pain without ST-segment elevation myocardial infarction was conducted in three EMS agencies between 12/2016-4/2018. During transport, paramedics obtained a patient blood sample that was sent directly to the hospital core lab for troponin measurement. On ED arrival HEART Pathway assessments were completed by ED providers as part of standard care. ED providers were blinded to troponin results from EMS blood samples. To evaluate the potential impact on length of stay (LOS), the time difference between EMS blood draw and first clinical ED draw was calculated. To determine the safety of using troponin measures from EMS blood samples, the diagnostic performance of the HEART Pathway for 30-day major adverse cardiac events (MACE: composite of cardiac death, myocardial infarction (MI), coronary revascularization) was determined using EMS troponin plus arrival ED troponin and EMS troponin plus a serial 3-h ED troponin.
RESULTS: The use of EMS blood samples for troponin measures among 401 patients presenting with acute chest pain resulted in a mean potential reduction in LOS of 72.5 ± SD 35.7 min. MACE at 30 days occurred in 21.0% (84/401), with 1 cardiac death, 78 MIs, and 5 revascularizations without MI. Use of the HEART Pathway with EMS and ED arrival troponin measures yielded a NPV of 98.0% (95% CI: 89.6-100). NPV improved to 100% (95% CI: 92.9-100) when using the EMS and 3-h ED troponin measures.
CONCLUSIONS: EMS blood collection used for core lab ED troponin measures could significantly reduce ED LOS and appears safe when integrated into the HEART Pathway.
参考来源
- Stopyra JP, Snavely AC, Ashburn NP, et al. EMS blood collection from patients with acute chest pain reduces emergency department length of stay. Am J Emerg Med. 2021. PMID: 33964547. doi:10.1016/j.ajem.2021.04.073
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。